

Sergey Tereshchenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2028618/publications.pdf>

Version: 2024-02-01

65
papers

7,288
citations

377584

21
h-index

97045

71
g-index

87
all docs

87
docs citations

87
times ranked

8200
citing authors

#	ARTICLE	IF	CITATIONS
1	ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19) Tj ETQq1 1 0.784314 rgBT /Overlock with COVID-19 on the prognosis. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 32-47.	0.2	10
2	Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. <i>Consilium Medicum</i> , 2022, 24, 28-35.	0.1	0
3	Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?. <i>Consilium Medicum</i> , 2022, 24, 7-12.	0.1	0
4	Chronic heart failure – modification of treatment paradigm. <i>Consilium Medicum</i> , 2022, 24, 13-19.	0.1	1
5	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	2.0	56
6	Predictive value of <i>Q</i>RS<i>T</i> complex duration in patients with chronic heart failure and atrial fibrillation: retrospective study. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 503-510.	0.2	0
7	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). <i>Terapevticheskii Arkhiv</i> , 2022, 94, 584-595.	0.2	9
8	SGLT2 inhibitors in acute decompensated heart failure, what do we know?. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 565-571.	0.2	1
9	The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 517-523.	0.2	2
10	Myocardial scintigraphy with ^{99m}Tc-pyrophosphate in the diagnosis of cardiac amyloidosis: place in the diagnostic algorithm, features of the implementation and interpretation of the study. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 530-537.	0.2	0
11	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
12	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
13	Prognostic impact of uric acid in patients with acute decompensated heart failure. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1066-1072.	0.2	0
14	Dynamics of Holter electrocardiogram monitoring in patients with chronic heart failure and atrial fibrillation on the background of cardiac contractility modulation. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1044-1051.	0.2	0
15	Myocardial remodeling in patients with chronic heart failure and implanted cardiac contractility modulators. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1443-1450.	0.2	1
16	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1491-1497.	0.2	6
17	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	1.6	145
18	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128

#	ARTICLE	IF	CITATIONS
19	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
20	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	3.8	340
21	Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion. <i>Russian Journal of Cardiology</i> , 2020, 25, 103-110.	0.4	5
22	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. <i>Russian Journal of Cardiology</i> , 2020, 25, 3919.	0.4	3
23	BYHEART observational trial of assessing exogenous phosphocreatine influence on the quality of life in patients with congestive heart failure. <i>Kardiologiya i Serdechno-Sosudistaya Khirurgiya</i> , 2020, 13, 168.	0.1	3
24	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	13.9	4,108
25	Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-14.	0.5	7
26	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	3.0	26
27	A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-CHF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	2.9	264
28	Stroke prevention in patients from Latin American countries with nonvalvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	0.7	16
29	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	1.2	45
30	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
31	Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT) $T_j ETQq1 1 0.784314 rgBT /Over$	0.7	16
32	Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. <i>Terapevticheskii Arkhiv</i> , 2019, 91, 67-73.	0.2	5
33	Pathological Remodeling of the Myocardium in Chronic Heart Failure: Role of PGC-1 β . <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 794-797.	0.3	14
34	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	1.0	28
35	IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 176-183.	0.3	1
36	NUCLEAR IMAGING IN THE DIAGNOSIS OF CARDIAC AMYLOIDOSIS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 94-100.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
38	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	1.1	80
39	Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3â€“Years Follow-up. <i>Kardiologiya</i> , 2018, 17, 14-22.	0.3	0
40	Neutrophil gelatinase-associated lipocalin for early diagnosis of acute kidney injury in patients with acute decompensated heart failure. <i>Kardiologiya</i> , 2018, 17, 44-50.	0.3	0
41	Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II. <i>Russian Journal of Cardiology</i> , 2018, , 22-27.	0.4	1
42	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
43	Impact of gender on event rates at 1â€“year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	0.8	30
44	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92
45	Modulation of Cardiac Contractility â€“ a New Method in the Treatment of Heart Failure. <i>Rational Pharmacotherapy in Cardiology</i> , 2016, 12, 574-581.	0.3	1
46	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€“AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	1.2	13
47	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
48	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118
49	PATHOPHYSIOLOGY OF ACUTE HEART FAILURE. WHATâ€™S NEW?. <i>Russian Journal of Cardiology</i> , 2016, , 52-64.	0.4	5
50	The use of optimal partitionings for multiparameter data analysis in clinical trials. <i>Mathematical Biology and Bioinformatics</i> , 2016, 11, 46-63.	0.1	8
51	IVABRADINE IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: NEW DATA FROM THE SHIFT MULTICENTER RANDOMIZED TRIAL. <i>Russian Journal of Cardiology</i> , 2016, , 80-85.	0.4	0
52	CLINICAL CASE OF USAGE OF SERELAXIN IN THE PATIENT WITH ACUTE DECOMPENSATED HEART FAILURE. <i>Russian Journal of Cardiology</i> , 2016, , 83-88.	0.4	1
53	The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 577-581.	0.3	10
54	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	0.9	74

#	ARTICLE	IF	CITATIONS
55	The Role of Markers of Organ Damage in Patients With Chronic Heart Failure. <i>Kardiologiya</i> , 2015, 1_2015, 70-76.	0.3	1
56	Cardiovascular pairing: modern methods of estimation, prognostic significance and possible clinical use in acute decompensation of chronic heart failure. <i>Medical News of North Caucasus</i> , 2015, 10, .	0.0	1
57	Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease. <i>Kardiologiya</i> , 2015, 2_2015, 37-41.	0.3	1
58	What We Know About Acute Decompensation of Heart Failure?. <i>Kardiologiya</i> , 2015, 4_2015, 91-96.	0.3	1
59	Long-term Antithrombotic Therapy for the Prevention of Thromboembolic Complications in Patients With Chronic Heart Failure. <i>Kardiologiya</i> , 2014, 6_2014, 86-90.	0.3	2
60	COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2013, 12, 29-33.	0.4	1
61	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
62	Effects of transluminal balloon angioplasty and stenting on the clinical course of ischemic chronic heart failure with preserved or reduced left ventricular ejection fraction: radionuclide 4D tomographic data. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2012, 11, 73-78.	0.4	0
63	Clinico-demographic characteristics of the patients with decompensated chronic heart failure. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2011, 10, 75-80.	0.4	0
64	The polymorphisms G(âˆˆ174)C in IL6 gene and G(âˆˆ1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome. <i>Molecular Biology</i> , 2010, 44, 741-747.	0.4	4
65	Polymorphic minisatellite ecNOS4a/4b of the endothelial NO synthase gene and cardiovascular disorders. <i>Molecular Biology</i> , 2000, 34, 744-746.	0.4	0